Cambridge - Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, notes the announcement from subsidiary company, Tetris Pharma Ltd, that Ogluo® (glucagon prefilled autoinjector pen) has been launched in the Netherlands as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.
Ogluo® has been launched in the Netherlands by Goodlife, under the previously announced, existing commercialisation agreement between Tetris Pharma Ltd and Goodlife, which has established Goodlife as the sole partner for the import, marketing and distribution of the product in the BeNeLux region.
See full Tetris Pharma announcement below:
Ogluo® launches in the Netherlands
Availability of glucagon prefilled autoinjector pen in first BeNeLux country, in partnership with Goodlife, further expands reach of Ogluo® across Europe. Continued momentum in pan European roll-out following earlier launches in Denmark, Norway, Austria, Germany and the UK
29 February 2024 - Tetris Pharma Ltd, a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in the Netherlands as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.
The launch is part of an existing exclusive commercialisation agreement between Tetris Pharma Ltd and Goodlife, announced in September 2023, which established Goodlife as the sole partner for the import, marketing and distribution of the product in the BeNeLux region.
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an auto-injector for patients within the licenced indication living with diabetes suffering from severe hypoglycaemia. Today’s launch builds on the continued roll-out of Ogluo® across key European markets, including, Denmark, Norway, Austria, Germany and the UK, as part of Tetris Pharma’s pan-European commercialisation programme.
Dr. Helen Parris, Senior Vice President, Commercial and General Manager of Tetris Pharma, commented: “The launch of Ogluo® in the Netherlands presents a significant milestone for Tetris Pharma, strengthening the commercial reach and pan-European presence of this important product and giving patients living with diabetes who may experience severe hypoglycaemia, a treatment option to tackle those events. Goodlife’s leading know-how and expertise of regional market dynamics make them an ideal partner to support with the roll-out of Ogluo® in the BeNeLux region. We look forward to continuing to expand our reach within Europe to bring this treatment option to people living with diabetes."
